Bile acid diarrhoea and FGF19: New views on diagnosis, pathogenesis and therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 7, 2014, Pages 428-434

  Walters, Julian R F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; EPITESTOSTERONE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; TAUROSELCHOLIC ACID; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

BILE ACID DIARRHEA; BILE ACID FECES LEVEL; BILE ACID SYNTHESIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE MARKER; DYSBIOSIS; FECES LEVEL; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; REVIEW; ANIMAL; CHEMISTRY; CHRONIC DISEASE; FECES; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHRONIC DISEASE; DIARRHEA; FECES; FIBROBLAST GROWTH FACTORS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84903814274     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.32     Document Type: Review

References (90)

1. Hofmann, A. F. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology 52, 752-757 (1967).
2. Cosnes, J. et al. Classification of the sequelae of bowel resection for Crohn's disease. Br. J. Surg. 81, 1627-1631 (1994). (Pubitemid 24349938)
3. Jung, D., Fantin, A. C., Scheurer, U., Fried, M. & Kullak-Ublick, G. A. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 53, 78-84 (2004). (Pubitemid 38083014)
4. Hofmann, A. F. & Poley, J. R. Cholestyramine treatment of diarrhea associated with ileal resection. N. Engl. J. Med. 281, 397-402 (1969).
5. Thaysen, E. H. & Pedersen, L. Idiopathic bile acid catharsis. Gut 17, 965-970 (1976). (Pubitemid 8027541)
6. Thomas, P. D. et al. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 52 (Suppl. 5), v1-v15 (2003). (Pubitemid 36760654)
7. Spiller, R. C. & Thompson, W. G. Bowel disorders. Am. J. Gastroenterol. 105, 775-785 (2010).
8. Fromm, H. & Malavolti, M. Bile acid-induced diarrhoea. Clin. Gastroenterol. 15, 567-582 (1986). (Pubitemid 16009181)
9. van Tilburg, A. J., de Rooij, F. W., van den Berg, J. W. & van Blankenstein, M. Primary bile acid diarrhoea without an ileal carrier defect: quantification of active bile acid transport across the ileal brush border membrane. Gut 32, 500-503 (1991).
10. van Tilburg, A. J., de Rooij, F. W., van den Berg, J. W. & van Blankenstein, M. Primary bile acid malabsorption: a pathophysiologic and clinical entity? Scand. J. Gastroenterol. Suppl. 194, 66-70 (1992). (Pubitemid 23106337)
11. Bajor, A. et al. Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption. Eur. J. Gastroenterol. Hepatol. 18, 397-403 (2006).
12. Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591 (2003). (Pubitemid 36828786)
13. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell. Metab. 2, 217-225 (2005).
14. Walters, J. R. F. et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol. 7, 1189-1194 (2009).
15. Hofmann, A. F. Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. Expert Rev. Gastroenterol. Hepatol. 3, 461-464 (2009).
16. Walters, J. R. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev. Gastroenterol. Hepatol. 4, 561-567 (2010).
17. Gracie, D. J. et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol. Motil. 24, 983-e538 (2012).
18. Khalid, U., Lalji, A., Stafferton, R. & Andreyev, J. Bile acid malabsorption: a forgotten diagnosis? Clin. Medicine 10, 124-126 (2010).
19. Waters, J. For 40 years, doctors said I had IBS. In fact it was a hormone problem cured by a simple pill. Daily Mail (1 Jan 2013).
20. Vijayvargiya, P., Camilleri, M., Shin, A. & Saenger, A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin. Gastroenterol. Hepatol. 11, 1232-1239 (2013).
21. Thaysen, E. H., Orholm, M., Arnfred, T., Carl, J. & Rodbro, P. Assessment of ileal function by abdominal counting of the retention of a γ emitting bile acid analogue. Gut 23, 862-865 (1982). (Pubitemid 12018515)
22. Boyd, G. S., Merrick, M. V., Monks, R. & Thomas, I. L. Se-75-labeled bile acid analogs, new radiopharmaceuticals for investigating the enterohepatic circulation. J. Nucl. Med. 22, 720-725 (1981). (Pubitemid 11040089)
23. Merrick, M. V., Eastwood, M. A. & Ford, M. J. Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention. Br. Med. J. (Clin. Res. Ed.) 290, 665-668 (1985). (Pubitemid 15103859)
24. Sciarretta, G. et al. 75SeHCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut 28, 970-975 (1987). (Pubitemid 17136877)
25. Hofmann, A. F. Enterohepatic circulation of bile acids. Compr. Physiol. 567-596 (2011).
26. Walters, J. R. F. & Pattni, S. S. Managing bile acid diarrhoea. Ther. Adv. Gastroenterol. 3, 349-357 (2010).
27. Peters, A. M. & Walters, J. R. Recycling rate of bile acids in the enterohepatic recirculation as a major determinant of whole body 75SeHCAT retention. Eur. J. Nucl. Med. Mol. Imaging 40, 1618-1621 (2013).
28. Nyhlin, H., Merrick, M. V. & Eastwood, M. A. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 35, 90-93 (1994). (Pubitemid 24059479)
29. Smith, M. J. et al. Bile acid malabsorption in persistent diarrhoea. J. R. Coll. Physicians Lond. 34, 448-451 (2000).
30. Wedlake, L., A'Hern, R., Thomas, K., Walters, J. R. F. & Andreyev, H. J. N. Systematic review: the prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Aliment. Pharmacol. Ther. 30, 707-717 (2009).
31. Borghede, M. K. et al. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine (75SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhoea. Eur. J. Intern. Med. 22, e137-e140 (2011).
32. Kurien, M. et al. Bile acid malabsorption: an under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand. J. Gastroenterol. 46, 818-822 (2011).
33. Pattni, S. S. et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment. Pharmacol. Ther. 38, 967-976 (2013).
34. Smith, M. J. & Perkins, A. C. A survey of the clinical use of SeHCAT in the UK. Nucl. Med. Commun. 34, 306-313 (2013).
35. NICE. National Institute for Health and Care Excellence [online]. SeHCAT (Tauroselcholic [75Selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss. http://guidance. nice.org.uk/DT/8 (2013).
36. Eusufzai, S. Bile acid malabsorption in patients with chronic diarrhoea. Scand. J. Gastroenterol. 28, 865-868 (1993). (Pubitemid 23294758)
37. Brydon, W. G., Nyhlin, H., Eastwood, M. A. & Merrick, M. V. Serum 7 α-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur. J. Gastroenterol. Hepatol. 8, 117-123 (1996). (Pubitemid 26130232)
38. Sauter, G. H., Munzing, W., von, R. C. & Paumgartner, G. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7α-hydroxy-4-cholesten-3-one in serum. Dig. Dis. Sci. 44, 14-19 (1999). (Pubitemid 29053072)
39. Brydon, W. G. et al. An evaluation of the use of serum 7-α-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea. Can. J. Gastroenterol. 25, 319-323 (2011).
40. Lundasen, T., Galman, C., Angelin, B. & Rudling, M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260, 530-536 (2006). (Pubitemid 44772372)
41. Galman, C., Angelin, B. & Rudling, M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J. Intern. Med. 270, 580-588 (2011).
42. Camilleri, M. et al. Measurement of serum 7α-hydroxy-4-cholesten-3- one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol. Motil. 21, 734-e43 (2009).
43. Wong, B. S. et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin. Gastroenterol. Hepatol. 10, 1009-1015 (2012).
44. Porter, J. L. et al. Accurate enzymatic measurement of fecal bile acids in patients with malabsorption. J. Lab. Clin. Med. 141, 411-418 (2003). (Pubitemid 36737154)
45. Duboc, H. et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24, 513-517 (2012).
46. Shin, A. et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 11, 1270-1275 (2013).
47. Mekjian, H. S., Phillips, S. F. & Hofmann, A. F. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J. Clin. Invest. 50, 1569-1577 (1971).
48. Binder, H. J. & Rawlins, C. L. Effect of conjugated dihydroxy bile salts on electrolyte transport in rat colon. J. Clin. Invest. 52, 1460-1466 (1973).
49. Keely, S. J. et al. Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G290-G297 (2007). (Pubitemid 46090271)
50. Covington, J. A. et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors (Basel) 13, 11899-11912 (2013).
51. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999). (Pubitemid 29289663)
52. Parks, D. J. et al. Bile acids: natural ligands for an orphan receptor. Science 284, 1365-1368 (1999). (Pubitemid 29289664)
53. Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3, 543-553 (1999). (Pubitemid 29268438)
54. Jones, S. A. Physiology of FGF15/19. Adv. Exp. Med. Biol. 728, 171-182 (2012).
55. Oelkers, P., Kirby, L. C., Heubi, J. E. & Dawson, P. A. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J. Clin. Invest. 99, 1880-1887 (1997). (Pubitemid 27175935)
56. Montagnani, M., Love, M. W., Rössel, P., Dawson, P. A. & Qvist, P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol. 36, 1077-1080 (2001). (Pubitemid 32801694)
57. Pattni, S. S., Brydon, W. G., Dew, T. & Walters, J. R. F. Fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin. Trans. Gastroenterol. 3, e18 (2012).
58. Yu, C. et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 275, 15482-15489 (2000). (Pubitemid 30337280)
59. Ito, S. et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho. J. Clin. Invest. 115, 2202-2208 (2005). (Pubitemid 41134162)
60. Jung, D. et al. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48, 2693-2700 (2007). (Pubitemid 350272854)
61. Pai, R. et al. Antibody-mediated inhibition of fibroblast growth factor-19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci. 126, 446-456 (2012).
62. Yu, X. X. et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS ONE 8, e66923 (2013).
63. Wong, B. S. et al. A Klotho-β variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 140, 1934-1942 (2011).
64. Rao, A. S. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139, 1549-1558 (2010).
65. Wong, B. S. et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig. Dis. Sci. 57, 1222-1226 (2012).
66. Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463-472 (2011).
67. Lenicek, M. et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel. Dis. 17, 1322-1327 (2010).
68. Nolan, J. D., Johnston, I. M. & Walters, J. R. Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective. Expert Rev. Gastroenterol. Hepatol. 7, 49-56 (2013).
69. Vergnes, L., Lee, J. M., Chin, R. G., Auwerx, J. & Reue, K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab. 17, 916-928 (2013).
70. Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624 (2011).
71. Stejskal, D., Karpisek, M., Hanulova, Z. & Stejskal, P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand. J. Clin. Lab. Invest. 68, 501-507 (2008).
72. Pournaras, D. J. et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153, 3613-3619 (2012).
73. Sadik, R., Abrahamsson, H., Ung, K.-A. & Stotzer, P.-O. Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am. J. Gastroenterol. 99, 711-718 (2004). (Pubitemid 38607976)
74. Fu, T. et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc. Natl Acad. Sci. USA 109, 16137-16142 (2012).
75. Miyata, M. et al. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J. Steroid Biochem. Mol. Biol. 132, 41-47 (2012).
76. Schmidt, D. R. et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 285, 14486-14494 (2010).
77. Zhang, J. H. et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G940-G948 (2013).
78. Pellicciari, R. et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572 (2002). (Pubitemid 34856095)
79. Mroz, M. S. et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut http://dx.doi.org/10.1136/gutjnl-2013-305088.
80. Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440 (2003). (Pubitemid 36800434)
81. Maruyama, T. et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719 (2002). (Pubitemid 35356798)
82. Alemi, F. et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145-154 (2013).
83. Pellicciari, R. et al. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52, 7958-7961 (2009).
84. Ward, J. B., Mroz, M. S. & Keely, S. J. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. Neurogastroenterol. Motil. 25, 708-711 (2013).
85. Iguchi, Y. et al. Effects of chemical modification of ursodeoxycholic acid on TGR5 activation. Biol. Pharm. Bull. 34, 1-7 (2011).
86. Camilleri, M. et al. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol. Motil. 23, 995-999 (2011).
87. Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225-235 (2013).
88. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01473524?term=NCT01473524 (2013).
89. Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582 (2013).
90. Johnston, I. M., Nolan, J. D., Dew, T., Shapiro, D. & Walters, J. R. F. A new therapy for chronic diarrhea? A proof of concept study of the FXR agonist obeticholic acid in patients with primary bile acid diarrhea. Gastroenterology 144, S60 (2013).